Photo from wikipedia
Dupilumab is an effective and safe medicine for the management of severe asthma. Due to its high cost, concerns are generated regarding its cost‐effectiveness. This study aimed to estimate the… Click to show full abstract
Dupilumab is an effective and safe medicine for the management of severe asthma. Due to its high cost, concerns are generated regarding its cost‐effectiveness. This study aimed to estimate the cost‐utility of dupilumab plus standard of care (SoC) versus SoC alone in children between 6 and 11 years old with severe asthma and eosinophilic phenotype.
Keywords:
cost;
dupilumab;
severe asthma;
cost utility
Journal Title: Pediatric Pulmonology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Pediatric Pulmonology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!